|
2022-04-13 |
2022-04-11 |
PS
Planned sale
|
Kutok Jeffery
Chief Scientific Officer
Officer
|
2,741
-2.8%
0.90
USD 2,467
|
2,741
-2.8%
|
0.90
|
USD 2,467
|
|
|
2022-02-09 |
2022-02-07 |
PS
Planned sale
|
Agarwal Shefali
See Remarks
Officer
|
1,058
-0.7%
1.50
USD 1,587
|
1,058
-0.7%
|
1.50
|
USD 1,587
|
|
|
2022-02-09 |
2022-02-07 |
PS
Planned sale
|
Beaulieu Joseph
Corporate Controller
Officer
|
222
-0.8%
1.50
USD 333
|
222
-0.8%
|
1.50
|
USD 333
|
|
|
2022-02-04 |
2022-02-02 |
PS
Planned sale
|
Agarwal Shefali
See Remarks
Officer
|
2,639
-1.6%
1.37
USD 3,615
|
2,639
-1.6%
|
1.37
|
USD 3,615
|
|
|
2022-02-04 |
2022-02-02 |
PS
Planned sale
|
Beaulieu Joseph
Corporate Controller
Officer
|
687
-2.3%
1.37
USD 941
|
687
-2.3%
|
1.37
|
USD 941
|
|
|
2022-02-04 |
2022-02-02 |
PS
Planned sale
|
Kutok Jeffery
Chief Scientific Officer
Officer
|
2,556
-2.6%
1.37
USD 3,502
|
2,556
-2.6%
|
1.37
|
USD 3,502
|
|
|
2022-02-01 |
2022-01-31 |
B
Purchase
|
Legorreta Pablo G.
Non-Executive Director
Large shareholder
|
22,666,667
+247.3%
1.50
USD 34,000,001
|
22,666,667
+247.3%
|
1.50
|
USD 34,000,001
|
|
|
2022-01-28 |
2022-01-26 |
PS
Planned sale
|
Agarwal Shefali
See Remarks
Officer
|
2,922
-1.8%
2.02
USD 5,902
|
2,922
-1.8%
|
2.02
|
USD 5,902
|
|
|
2021-12-07 |
2021-12-06 |
PS
Planned sale
|
Agarwal Shefali
See Remarks
Officer
|
1,780
-1.1%
2.93
USD 5,215
|
1,780
-1.1%
|
2.93
|
USD 5,215
|
|
|
2021-03-29 |
2021-03-26 |
B
Purchase
|
MOTT DAVID M
Non-Executive Director
|
217
+0.1%
7.80
USD 1,693
|
217
+0.1%
|
7.80
|
USD 1,693
|
|
|
2021-03-29 |
2021-03-26 |
B
Purchase
|
MOTT DAVID M
Non-Executive Director
|
34,269
+29.4%
7.97
USD 273,124
|
34,269
+29.4%
|
7.97
|
USD 273,124
|
|
|
2021-03-29 |
2021-03-25 |
PS
Planned sale
|
Bazemore Robert B
President & CEO
Executive Director
|
10,328
-3.1%
7.85
USD 81,075
|
10,328
-3.1%
|
7.85
|
USD 81,075
|
|
|
2021-03-29 |
2021-03-25 |
B
Purchase
|
MOTT DAVID M
Non-Executive Director
|
28,231
+32.0%
7.98
USD 225,283
|
28,231
+32.0%
|
7.98
|
USD 225,283
|
|
|
2021-02-05 |
2021-02-04 |
PS
Planned sale
|
Beaulieu Joseph
Corporate Controller
Officer
|
227
-1.7%
11.21
USD 2,545
|
227
-1.7%
|
11.21
|
USD 2,545
|
|
|
2021-02-05 |
2021-02-04 |
PS
Planned sale
|
Ros Matthew
See Remarks
Officer
|
894
-1.1%
11.21
USD 10,022
|
894
-1.1%
|
11.21
|
USD 10,022
|
|
|
2021-02-05 |
2021-02-04 |
PS
Planned sale
|
Agarwal Shefali
Chief Medical Officer
Officer
|
969
-0.9%
11.21
USD 10,862
|
969
-0.9%
|
11.21
|
USD 10,862
|
|
|
2021-02-05 |
2021-02-04 |
PS
Planned sale
|
TOMBESI PAOLO
Chief Financial Officer
Officer
|
1,021
-1.9%
11.21
USD 11,445
|
1,021
-1.9%
|
11.21
|
USD 11,445
|
|
|
2021-02-05 |
2021-02-04 |
PS
Planned sale
|
Bazemore Robert B
President & CEO
Executive Director
|
3,890
-1.2%
11.21
USD 43,607
|
3,890
-1.2%
|
11.21
|
USD 43,607
|
|
|
2021-02-05 |
2021-02-04 |
PS
Planned sale
|
Vakiener Victoria
Chief Commercial Officer
Officer
|
817
-1.5%
11.21
USD 9,159
|
817
-1.5%
|
11.21
|
USD 9,159
|
|
|
2021-01-27 |
2021-01-25 |
PS
Planned sale
|
Ros Matthew
See Remarks
Officer
|
2,872
-4.9%
11.41
USD 32,770
|
2,872
-4.9%
|
11.41
|
USD 32,770
|
|
|
2021-01-27 |
2021-01-25 |
PS
Planned sale
|
Bazemore Robert B
President & CEO
Executive Director
|
6,069
-2.4%
11.41
USD 69,247
|
6,069
-2.4%
|
11.41
|
USD 69,247
|
|
|
2021-01-27 |
2021-01-25 |
PS
Planned sale
|
Agarwal Shefali
Chief Medical Officer
Officer
|
2,872
-3.7%
11.41
USD 32,770
|
2,872
-3.7%
|
11.41
|
USD 32,770
|
|
|
2021-01-27 |
2021-01-25 |
PS
Planned sale
|
Vakiener Victoria
Chief Commercial Officer
Officer
|
599
-2.1%
11.41
USD 6,835
|
599
-2.1%
|
11.41
|
USD 6,835
|
|
|
2020-12-07 |
2020-12-03 |
PS
Planned sale
|
Agarwal Shefali
Chief Medical Officer
Officer
|
2,522
-3.2%
13.54
USD 34,148
|
2,522
-3.2%
|
13.54
|
USD 34,148
|
|
|
2020-11-13 |
2020-11-11 |
B
Purchase
|
GOLDFISCHER CARL
Non-Executive Director
|
5,000
+inf%
12.07
USD 60,350
|
5,000
+inf%
|
12.07
|
USD 60,350
|
|
|
2020-09-03 |
2020-09-02 |
PS
Planned sale
|
Beaulieu Joseph
Corporate Controller
Officer
|
543
-8.4%
12.88
USD 6,994
|
543
-8.4%
|
12.88
|
USD 6,994
|
|
|
2020-06-26 |
2020-06-26 |
B
Purchase
|
MOTT DAVID M
Non-Executive Director
|
62,019
+301.3%
16.03
USD 994,165
|
62,019
+301.3%
|
16.03
|
USD 994,165
|
|
|
2020-06-22 |
2020-06-18 |
PS
Planned sale
|
Ros Matthew
See Remarks
Officer
|
68,651
-57.0%
21.65
USD 1,486,294
|
68,651
-57.0%
|
21.65
|
USD 1,486,294
|
|
|
2020-06-22 |
2020-06-18 |
PS
Planned sale
|
Ros Matthew
See Remarks
Officer
|
2,289
-4.2%
22.00
USD 50,358
|
2,289
-4.2%
|
22.00
|
USD 50,358
|
|
|
2020-06-22 |
2020-06-18 |
PS
Planned sale
|
Ros Matthew
See Remarks
Officer
|
41,063
-44.2%
20.50
USD 841,792
|
41,063
-44.2%
|
20.50
|
USD 841,792
|
|
|
2020-06-22 |
2020-06-18 |
S
Sale
|
Bazemore Robert B
President & CEO
Executive Director
|
10,000
-3.9%
22.00
USD 220,000
|
10,000
-3.9%
|
22.00
|
USD 220,000
|
|
|
2020-06-22 |
2020-06-18 |
S
Sale
|
Bazemore Robert B
President & CEO
Executive Director
|
10,000
-3.8%
22.00
USD 220,000
|
10,000
-3.8%
|
22.00
|
USD 220,000
|
|
|
2020-03-26 |
2020-03-25 |
PS
Planned sale
|
Beaulieu Joseph
Corporate Controller
Officer
|
212
-4.1%
15.28
USD 3,239
|
212
-4.1%
|
15.28
|
USD 3,239
|
|
|
2020-03-26 |
2020-03-25 |
PS
Planned sale
|
Agarwal Shefali
Chief Medical Officer
Officer
|
1,243
-1.7%
15.28
USD 18,993
|
1,243
-1.7%
|
15.28
|
USD 18,993
|
|
|
2020-03-26 |
2020-03-25 |
PS
Planned sale
|
Ros Matthew
See Remarks
Officer
|
1,243
-2.3%
15.28
USD 18,993
|
1,243
-2.3%
|
15.28
|
USD 18,993
|
|
|
2020-03-26 |
2020-03-25 |
PS
Planned sale
|
TOMBESI PAOLO
Chief Financial Officer
Officer
|
1,243
-7.5%
15.28
USD 18,993
|
1,243
-7.5%
|
15.28
|
USD 18,993
|
|
|
2020-03-26 |
2020-03-25 |
PS
Planned sale
|
Bazemore Robert B
President & CEO
Executive Director
|
3,285
-1.3%
15.28
USD 50,195
|
3,285
-1.3%
|
15.28
|
USD 50,195
|
|
|
2020-03-05 |
2020-03-03 |
PS
Planned sale
|
Beaulieu Joseph
Corporate Controller
Officer
|
996
-21.6%
22.18
USD 22,091
|
996
-21.6%
|
22.18
|
USD 22,091
|
|
|
2020-01-27 |
2020-01-27 |
PS
Planned sale
|
Bazemore Robert B
President & CEO
Executive Director
|
6,074
-6.7%
20.44
USD 124,153
|
6,074
-6.7%
|
20.44
|
USD 124,153
|
|
|
2020-01-27 |
2020-01-27 |
PS
Planned sale
|
Agarwal Shefali
Chief Medical Officer
|
2,630
-4.3%
20.44
USD 53,757
|
2,630
-4.3%
|
20.44
|
USD 53,757
|
|
|
2020-01-27 |
2020-01-24 |
PS
Planned sale
|
Bazemore Robert B
President & CEO
Executive Director
|
3,002
-3.2%
24.62
USD 73,909
|
3,002
-3.2%
|
24.62
|
USD 73,909
|
|
|
2020-01-27 |
2020-01-24 |
PS
Planned sale
|
Ros Matthew
See Remarks
|
1,847
-4.2%
24.64
USD 45,510
|
1,847
-4.2%
|
24.64
|
USD 45,510
|
|
|
2020-01-27 |
2020-01-24 |
PS
Planned sale
|
Beaulieu Joseph
Corporate Controller
|
330
-24.1%
24.63
USD 8,128
|
330
-24.1%
|
24.63
|
USD 8,128
|
|
|
2020-01-27 |
2020-01-24 |
PS
Planned sale
|
Agarwal Shefali
Chief Medical Officer
|
1,843
-2.9%
24.64
USD 45,412
|
1,843
-2.9%
|
24.64
|
USD 45,412
|
|
|
2020-09-03 |
2019-09-03 |
PS
Planned sale
|
Beaulieu Joseph
Corporate Controller
Officer
|
971
-13.0%
12.77
USD 12,400
|
971
-13.0%
|
12.77
|
USD 12,400
|
|
|
2019-06-28 |
2019-06-27 |
S
Sale
|
MOTT DAVID M
|
52,473
-100.0%
12.43
USD 652,134
|
52,473
-100.0%
|
12.43
|
USD 652,134
|
|
|
2019-06-26 |
2019-06-26 |
S
Sale
|
MOTT DAVID M
|
52,472
-50.0%
12.85
USD 674,176
|
52,472
-50.0%
|
12.85
|
USD 674,176
|
|
|
2019-06-26 |
2019-06-25 |
S
Sale
|
MOTT DAVID M
|
52,472
-33.3%
13.31
USD 698,649
|
52,472
-33.3%
|
13.31
|
USD 698,649
|
|
|
2019-06-17 |
2019-06-14 |
PS
Planned sale
|
Agarwal Shefali
Chief Medical Officer
|
1,195
-3.2%
11.97
USD 14,304
|
1,195
-3.2%
|
11.97
|
USD 14,304
|
|
|
2019-06-14 |
2019-06-13 |
PS
Planned sale
|
Bazemore Robert B
President & CEO
Executive Director
|
2,074
-2.4%
12.10
USD 25,095
|
2,074
-2.4%
|
12.10
|
USD 25,095
|
|
|
2019-06-14 |
2019-06-13 |
PS
Planned sale
|
Ros Matthew
See Remarks
|
1,185
-2.9%
12.10
USD 14,339
|
1,185
-2.9%
|
12.10
|
USD 14,339
|
|
|
2019-06-14 |
2019-06-13 |
PS
Planned sale
|
Beaulieu Joseph
Corporate Controller
|
203
-29.0%
12.10
USD 2,456
|
203
-29.0%
|
12.10
|
USD 2,456
|
|
|
2018-10-05 |
2018-10-05 |
B
Purchase
|
MOTT DAVID M
Non-Executive Director
|
416,667
+6.9%
9.00
USD 3,750,003
|
416,667
+6.9%
|
9.00
|
USD 3,750,003
|
|
|
2018-02-06 |
2018-02-05 |
S
Sale
|
Ros Matthew
Chief Operating Officer
Officer
|
519
-16.6%
17.20
USD 8,927
|
519
-16.6%
|
17.20
|
USD 8,927
|
|
|
2018-02-06 |
2018-02-05 |
S
Sale
|
Ros Matthew
Chief Operating Officer
Officer
|
71,745
-95.8%
16.63
USD 1,192,768
|
71,745
-95.8%
|
16.63
|
USD 1,192,768
|
|
|
2017-10-25 |
2017-10-24 |
S
Sale
|
Ho Peter Tai-Ching
Chief Development Officer
|
15,000
-64.9%
16.44
USD 246,591
|
15,000
-64.9%
|
16.44
|
USD 246,591
|
|
|
2017-09-26 |
2017-09-25 |
S
Sale
|
Ho Peter Tai-Ching
Chief Development Officer
|
15,000
-64.9%
16.81
USD 252,077
|
15,000
-64.9%
|
16.81
|
USD 252,077
|
|
|
2017-09-18 |
2017-09-18 |
B
Purchase
|
MOTT DAVID M
|
200,000
+3.4%
15.25
USD 3,050,000
|
200,000
+3.4%
|
15.25
|
USD 3,050,000
|
|
|
2017-08-28 |
2017-08-24 |
S
Sale
|
Ho Peter Tai-Ching
Chief Development Officer
|
15,000
-67.5%
15.68
USD 235,266
|
15,000
-67.5%
|
15.68
|
USD 235,266
|
|
|
2017-07-26 |
2017-07-24 |
S
Sale
|
Ho Peter Tai-Ching
Chief Development Officer
Officer
|
15,000
-67.5%
13.44
USD 201,572
|
15,000
-67.5%
|
13.44
|
USD 201,572
|
|
|
2017-07-05 |
2017-06-30 |
PS
Planned sale
|
Singer Andrew E.
EVP & CFO
Officer
|
3,024
-6.9%
15.50
USD 46,872
|
3,024
-6.9%
|
15.50
|
USD 46,872
|
|
|
2017-06-27 |
2017-06-26 |
S
Sale
|
Ho Peter Tai-Ching
Chief Development Officer
|
15,000
-67.5%
14.87
USD 223,115
|
15,000
-67.5%
|
14.87
|
USD 223,115
|
|
|
2017-06-07 |
2017-06-06 |
S
Sale
|
Copeland Robert A
President of Research and CSO
|
2,500
-7.3%
13.45
USD 33,625
|
2,500
-7.3%
|
13.45
|
USD 33,625
|
|
|
2017-05-26 |
2017-05-25 |
S
Sale
|
Ho Peter Tai-Ching
Chief Development Officer
Officer
|
15,000
-67.5%
16.11
USD 241,664
|
15,000
-67.5%
|
16.11
|
USD 241,664
|
|
|
2017-05-03 |
2017-05-02 |
S
Sale
|
Copeland Robert A
President of Research and CSO
Officer
|
5,000
-13.7%
17.44
USD 87,213
|
5,000
-13.7%
|
17.44
|
USD 87,213
|
|
|
2017-04-05 |
2017-04-04 |
S
Sale
|
Copeland Robert A
President of Research and CSO
|
2,500
-7.3%
16.36
USD 40,896
|
2,500
-7.3%
|
16.36
|
USD 40,896
|
|
|
2017-04-05 |
2017-04-04 |
S
Sale
|
Copeland Robert A
President of Research and CSO
|
2,500
-6.8%
16.36
USD 40,909
|
2,500
-6.8%
|
16.36
|
USD 40,909
|
|
|
2017-04-03 |
2017-03-31 |
PS
Planned sale
|
Singer Andrew E.
EVP & CFO
|
2,013
-5.3%
17.09
USD 34,394
|
2,013
-5.3%
|
17.09
|
USD 34,394
|
|
|
2017-01-10 |
2017-01-09 |
PS
Planned sale
|
Singer Andrew E.
EVP & CFO
|
1,013
-3.0%
12.04
USD 12,194
|
1,013
-3.0%
|
12.04
|
USD 12,194
|
|
|
2016-12-12 |
2016-12-09 |
PS
Planned sale
|
Singer Andrew E.
EVP & CFO
Officer
|
1,013
-3.1%
11.03
USD 11,172
|
1,013
-3.1%
|
11.03
|
USD 11,172
|
|
|
2016-12-12 |
2016-12-08 |
S
Sale
|
Ho Peter Tai-Ching
Chief Development Officer
Officer
|
200
-3.5%
10.89
USD 2,179
|
200
-3.5%
|
10.89
|
USD 2,179
|
|
|
2016-11-10 |
2016-11-09 |
PS
Planned sale
|
Singer Andrew E.
EVP & CFO
Officer
|
1,013
-3.2%
10.40
USD 10,535
|
1,013
-3.2%
|
10.40
|
USD 10,535
|
|
|
2016-10-12 |
2016-10-10 |
PS
Planned sale
|
Singer Andrew E.
EVP & CFO
Officer
|
1,013
-3.4%
9.72
USD 9,848
|
1,013
-3.4%
|
9.72
|
USD 9,848
|
|
|
2016-09-12 |
2016-09-09 |
PS
Planned sale
|
Singer Andrew E.
EVP & CFO
Officer
|
1,013
-3.6%
7.55
USD 7,651
|
1,013
-3.6%
|
7.55
|
USD 7,651
|
|
|
2016-08-10 |
2016-08-09 |
PS
Planned sale
|
Singer Andrew E.
EVP & CFO
Officer
|
1,013
-3.7%
9.05
USD 9,166
|
1,013
-3.7%
|
9.05
|
USD 9,166
|
|
